Corcept Therapeutics Inc (CORT) · Nov 3, 2026 · Earnings
Beat — Revenue $340.5M vs ~$323.9M consensus; diluted EPS $1.01 vs ~$0.79
Corcept earnings beat published Q3 expectations as Lifyorli revenue reached $91.4 million. The launch is scaling quickly, while 2026 guidance stays unchanged.
Corcept is transitioning from a Korlym-led endocrinology business into a two-product commercial company, with newly launched Lifyorli becoming the second growth engine. The quarter shows that transition is progressing faster than the market expected: published estimates centered near $323.9 million of revenue and roughly $0.79 of EPS, versus $340.5 million and $1.01 reported.
The commercial launch is the main positive surprise. Lifyorli generated $91.4 million in its second reported quarter, up 92% sequentially, while Korlym and authorized generic revenue still grew 19% to $249.1 million. The combination means growth is not yet dependent on one product replacing the other.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Product revenue, net (Income Statement) | $340.5M (+63.9%) | $207.6M | ~$323.9M |
| Diluted EPS (Income Statement) | $1.01 (+531.3%) | $0.16 | ~$0.79 |
| Korlym and authorized generic revenue (Revenue by product) | $249.1M (+20.0%) | $207.6M | |
| Lifyorli revenue (Revenue by product) | $91.4M | — | |
| Net income (Income Statement) | $126.8M (+544.6%) | $19.7M |
The beat strengthens execution, but management did not raise the bar. Corcept reiterated 2026 revenue guidance of $1.1 billion to $1.2 billion rather than increasing it after the strong quarter. That makes the earnings result clearly better than near-term expectations, but not a wholesale reset of the company’s outlook.
The pipeline adds upside, but most of the clinical headline was already public. BELLA Part A showed encouraging progression-free survival, response, and six-month survival results, especially in patients earlier in the platinum-resistant treatment course; however, those results were announced before this earnings release, so the filing mainly confirms and contextualizes them rather than creating a fresh clinical surprise. The more important new operational markers are that BELLA Part C enrollment is complete, BELLA Part B is nearing completion, and several results are expected by the end of 2027. 〔0〕
The next major binary event is regulatory, not another operating update. Corcept expects an FDA decision on its resubmitted relacorilant NDA by December 17, 2026, while European approval for the ovarian-cancer indication is expected by year-end. 〔1〕
Bottom line: This was a genuine earnings beat driven by rapid Lifyorli adoption on top of resilient Korlym sales. It improves the execution story, but the unchanged full-year guide keeps the impact moderate rather than transformational.
FDA decision on relacorilant NDA expected by December 17
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!